<p>BioLife Solutions, Inc.（纳斯达克代码：BLFS - 获取免费报告）在覆盖该股票的六家券商中获得了 “买入” 的共识评级，MarketBeat 报道。六位投资分析师对该股票给予了买入推荐。在过去一年中，给予该股票评级的券商的平均一年目标价为 31.17 美元。</p>
<p>获取 <strong>BioLife Solutions</strong> 的提醒：</p>
<ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
<p>几家券商最近对 BLFS 进行了评论。华尔街禅在周三的研究报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。HC Wainwright 在 5 月 13 日的报告中重申了 “买入” 评级，并设定了 BioLife Solutions 股票的 30.00 美元目标价。</p>
<p><strong>阅读我们关于 BioLife Solutions 的最新股票分析</strong></p>
<h2>BioLife Solutions 股票表现</h2>
<ul>
<li>3 只小型医疗股今天正在影响市场</li>
</ul>
<p>纳斯达克 BLFS 的股票在周五开盘价为 22.10 美元。该公司的流动比率为 2.78，速动比率为 1.78，债务股本比率为 0.03。BioLife Solutions 的 12 个月低点为 18.70 美元，12 个月高点为 29.55 美元。该股票的 50 日移动平均线为 23.27 美元，200 日移动平均线为 25.24 美元。该公司的市值为 10.5 亿美元，市盈率为-20.85，贝塔值为 2.01。</p>
<p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）最近一次发布财报是在 5 月 8 日，医疗设备提供商报告本季度每股收益为 0.04 美元，超出市场共识预期的-0.03 美元，超出幅度为 0.07 美元。BioLife Solutions 的股本回报率为-6.61%，净利润率为-38.98%。该公司本季度的收入为 2394 万美元，而市场共识预期为 2222 万美元。整体来看，股票研究分析师预测 BioLife Solutions 本年度将发布-0.3 美元的每股收益。</p>
<h2>内部买卖情况</h2>
<p>在其他 BioLife Solutions 的新闻中，首席营销官 Todd Berard 在 3 月 11 日的交易中出售了 1577 股 BioLife Solutions 股票。该股票以平均价格 25.00 美元出售，总价值为 39425.00 美元。交易完成后，首席营销官现在直接持有公司 104961 股股票，价值 2624025 美元。此次交易使其持股减少了 1.48%。该出售在与证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Troy Wichterman 在 3 月 11 日的交易中出售了 4151 股 BioLife Solutions 股票。该股票以平均价格 25.00 美元出售，总价值为 103775.00 美元。交易完成后，首席财务官现在直接持有公司 116809 股股票，价值 2920225 美元。这代表其持股减少了 3.43%。该出售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了 71696 股公司股票，价值 1665094 美元。内部人士持有公司 2.20% 的股份。</p>
<h2>对 BioLife Solutions 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Steward Partners Investment Advisory LLC 在第四季度获得了 BioLife Solutions 的新头寸，价值 26000 美元。Point72 Asia Singapore Pte. Ltd. 在第四季度获得了 BioLife Solutions 的新头寸，价值 31000 美元。怀俄明州在第一季度将其在 BioLife Solutions 的持股增加了 353.1%。怀俄明州现在持有 1912 股该医疗设备提供商的股票，价值 44000 美元，此前在上一季度增加了 1490 股。US Bancorp DE 在第一季度将其在 BioLife Solutions 的持股增加了 243.7%。US Bancorp DE 现在持有 2155 股该医疗设备提供商的股票，价值 49000 美元，此前在上一季度增加了 1528 股。最后，1620 Investment Advisors Inc. 在第四季度将其在 BioLife Solutions 的持股增加了 41.7%。1620 Investment Advisors Inc. 现在持有 2295 股该医疗设备提供商的股票，价值 60000 美元，此前在上一季度增加了 675 股。93.24% 的股票由机构投资者和对冲基金持有。</p>
<h2>BioLife Solutions 公司简介</h2>
<p>（获取免费报告）</p>
<p>BioLife Solutions, Inc. 在美国、欧洲、中东、非洲及国际市场开发、制造和销售用于细胞和基因治疗（CGT）行业的生物生产工具和服务。该公司的产品用于生物基疗法的基础和应用研究以及商业制造。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 BioLife Solutions</li>
<li>3 只证明仍然必不可少的杂货股票</li>
<li>Joby 股票的动荡：最近下跌的原因是什么？</li>
<li>深入分析买卖差价</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>复利及其在投资中的重要性</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于 BioLife Solutions 吗？</h2>
<p>在考虑 BioLife Solutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 BioLife Solutions 并不在名单上。</p>
<p>虽然 BioLife Solutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BLFS

<p>BioLife Solutions, Inc.（纳斯达克代码：BLFS）获得了六家券商的一致 “买入” 评级。平均目标价格为 31.17 美元。尽管 Wall Street Zen 将其评级下调至 “卖出”，但 HC Wainwright 仍维持 “买入” 评级，目标价为 30 美元。该股票开盘价为 22.10 美元，市值为 10.5 亿美元。最近的财报显示每股收益为 0.04 美元，超出预期。内部人士最近出售了部分股份，机构投资者持有 93.24% 的股份。BioLife 为细胞和基因治疗行业开发生物生产工具</p>

<p>BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) has been given a consensus rating of &#34;Buy&#34; by the six brokerages that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $31.17.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.（纳斯达克代码：BLFS - 获取免费报告）在覆盖该股票的六家券商中获得了 “买入” 的共识评级，MarketBeat 报道。六位投资分析师对该股票给予了买入推荐。在过去一年中，给予该股票评级的券商的平均一年目标价为 31.17 美元。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>BioLife Solutions</strong> 的提醒：</p>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在值得投资的最佳生物科技股票</li>
</ul>
</div><p>Several brokerages have recently commented on BLFS. Wall Street Zen downgraded BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday. HC Wainwright reissued a &#34;buy&#34; rating and set a $30.00 price target on shares of BioLife Solutions in a report on Tuesday, May 13th.</p>
<div class="lb-trans"><p>几家券商最近对 BLFS 进行了评论。华尔街禅在周三的研究报告中将 BioLife Solutions 的评级从 “持有” 下调至 “卖出”。HC Wainwright 在 5 月 13 日的报告中重申了 “买入” 评级，并设定了 BioLife Solutions 股票的 30.00 美元目标价。</p>
</div><p><strong>Read Our Latest Stock Analysis on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BioLife Solutions 的最新股票分析</strong></p>
</div><h2>BioLife Solutions Stock Performance</h2>
<div class="lb-trans"><h2>BioLife Solutions 股票表现</h2>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型医疗股今天正在影响市场</li>
</ul>
</div><p>Shares of NASDAQ BLFS opened at $22.10 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a 12 month low of $18.70 and a 12 month high of $29.55. The stock has a 50 day moving average of $23.27 and a 200-day moving average of $25.24. The company has a market capitalization of $1.05 billion, a P/E ratio of -20.85 and a beta of 2.01.</p>
<div class="lb-trans"><p>纳斯达克 BLFS 的股票在周五开盘价为 22.10 美元。该公司的流动比率为 2.78，速动比率为 1.78，债务股本比率为 0.03。BioLife Solutions 的 12 个月低点为 18.70 美元，12 个月高点为 29.55 美元。该股票的 50 日移动平均线为 23.27 美元，200 日移动平均线为 25.24 美元。该公司的市值为 10.5 亿美元，市盈率为-20.85，贝塔值为 2.01。</p>
</div><p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. As a group, equities research analysts predict that BioLife Solutions will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>BioLife Solutions（纳斯达克代码：BLFS - 获取免费报告）最近一次发布财报是在 5 月 8 日，医疗设备提供商报告本季度每股收益为 0.04 美元，超出市场共识预期的-0.03 美元，超出幅度为 0.07 美元。BioLife Solutions 的股本回报率为-6.61%，净利润率为-38.98%。该公司本季度的收入为 2394 万美元，而市场共识预期为 2222 万美元。整体来看，股票研究分析师预测 BioLife Solutions 本年度将发布-0.3 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><p>In other BioLife Solutions news, CMO Todd Berard sold 1,577 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the transaction, the chief marketing officer now directly owns 104,961 shares of the company's stock, valued at $2,624,025. The trade was a 1.48% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Troy Wichterman sold 4,151 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the completion of the transaction, the chief financial officer now directly owns 116,809 shares of the company's stock, valued at $2,920,225. This represents a 3.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,696 shares of company stock valued at $1,665,094. Insiders own 2.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 BioLife Solutions 的新闻中，首席营销官 Todd Berard 在 3 月 11 日的交易中出售了 1577 股 BioLife Solutions 股票。该股票以平均价格 25.00 美元出售，总价值为 39425.00 美元。交易完成后，首席营销官现在直接持有公司 104961 股股票，价值 2624025 美元。此次交易使其持股减少了 1.48%。该出售在与证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，首席财务官 Troy Wichterman 在 3 月 11 日的交易中出售了 4151 股 BioLife Solutions 股票。该股票以平均价格 25.00 美元出售，总价值为 103775.00 美元。交易完成后，首席财务官现在直接持有公司 116809 股股票，价值 2920225 美元。这代表其持股减少了 3.43%。该出售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了 71696 股公司股票，价值 1665094 美元。内部人士持有公司 2.20% 的股份。</p>
</div><h2>Hedge Funds Weigh In On BioLife Solutions</h2>
<div class="lb-trans"><h2>对 BioLife Solutions 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions in the 4th quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions in the 4th quarter valued at $31,000. State of Wyoming raised its holdings in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares in the last quarter. US Bancorp DE raised its holdings in BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,528 shares in the last quarter. Finally, 1620 Investment Advisors Inc. raised its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 675 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Steward Partners Investment Advisory LLC 在第四季度获得了 BioLife Solutions 的新头寸，价值 26000 美元。Point72 Asia Singapore Pte. Ltd. 在第四季度获得了 BioLife Solutions 的新头寸，价值 31000 美元。怀俄明州在第一季度将其在 BioLife Solutions 的持股增加了 353.1%。怀俄明州现在持有 1912 股该医疗设备提供商的股票，价值 44000 美元，此前在上一季度增加了 1490 股。US Bancorp DE 在第一季度将其在 BioLife Solutions 的持股增加了 243.7%。US Bancorp DE 现在持有 2155 股该医疗设备提供商的股票，价值 49000 美元，此前在上一季度增加了 1528 股。最后，1620 Investment Advisors Inc. 在第四季度将其在 BioLife Solutions 的持股增加了 41.7%。1620 Investment Advisors Inc. 现在持有 2295 股该医疗设备提供商的股票，价值 60000 美元，此前在上一季度增加了 675 股。93.24% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc. 在美国、欧洲、中东、非洲及国际市场开发、制造和销售用于细胞和基因治疗（CGT）行业的生物生产工具和服务。该公司的产品用于生物基疗法的基础和应用研究以及商业制造。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 BioLife Solutions</li>
<li>3 只证明仍然必不可少的杂货股票</li>
<li>Joby 股票的动荡：最近下跌的原因是什么？</li>
<li>深入分析买卖差价</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
<li>复利及其在投资中的重要性</li>
<li>超级微型计算机股票在沙特订单中开辟新路径</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于 BioLife Solutions 吗？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioLife Solutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 BioLife Solutions 并不在名单上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioLife Solutions 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BioLife Solutions, Inc.（纳斯达克股票代码：BLFS）被券商平均推荐为 “买入”